Among patients with diabetes who require in-center hemodialysis, the use of GLP-1 receptor agonists is associated with a lower risk of developing Alzheimer disease and related dementias compared with ...

A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be less likely to develop epilepsy than those taking DPP-4 inhibitors.

This is the latest study to suggest that GLP-1s, particularly semaglutide, are tied to a reduced risk for epilepsy in type 2 diabetes.

A new analysis suggests GLP 1 receptor agonists, the diabetes drugs that include semaglutide, dulaglutide and liraglutide, may be linked with a modestly lower risk of developing epilepsy in people ...

GLP-1 RAs show greater cardiovascular benefits in type 2 diabetes patients with BMI ≥25 compared to DPP-4 inhibitors. Kidney protection from GLP-1 RAs remains consistent across all BMI categories. The ...

Those prescribed a GLP-1 RA had a significantly increased risk for new chronic cough compared with those prescribed any non-GLP-1 RA second-line medication, DPP-4 inhibitor, or sulfonylurea in a ...

GLP-1 drugs show a potential link to reduced epilepsy risk in people with type 2 diabetes. People taking GLP-1 drugs were 16% less likely to develop epilepsy than those on DPP-4 inhibitors.

Relative to GLP-1RA and DPP-4 inhibitor use, SGLT2 inhibitor use was associated with an increased risk for erythrocytosis but not an increased risk for thrombosis in T2D. Among individuals with type 2 ...

A large US-based study has found that people with type 2 diabetes taking GLP-1 drugs such as Ozempic may be slightly less likely to develop epilepsy than those on older diabetes medications. While the ...

Medically reviewed by Kristie Reed, PharmD The best time of day to take medication for diabetes varies, depending on the type of medication. Some medications should be taken with food to lessen the ...

Researchers caution that while the findings are promising, the observational study does not prove that GLP-1 drugs prevent ...